NYSE:LLYPharmaceuticals
Eli Lilly Retevmo Trial Success And Valuation Signal Potential Upside
Eli Lilly (NYSE:LLY) reported landmark Phase 3 results for Retevmo as adjuvant therapy in early-stage RET fusion-positive non-small cell lung cancer.
The LIBRETTO-432 trial found an 83% reduction in the risk of disease recurrence or death versus placebo, based on event-free survival.
Data were presented at ASCO and published in a leading journal, with global regulatory submissions planned.
Eli Lilly, known for its portfolio in oncology and other therapeutic areas, is adding another piece to...